Company Overview
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets. It develops MT-601, which is in Phase 1 trials for the treatment of lymphoma and pancreatic cancer; and MT-401-OTS, which is in a Phase 1 trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company was formerly known as TapImmune, Inc. and changed its name to Marker Therapeutics, Inc. in October 2018. Marker Therapeutics, Inc. was founded in 1999 and is headquartered in Houston, Texas.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -0.78% |
| 6 Months: | -12.93% |
| 3 Months: | -12.33% |
| 1 Month: | +14.29% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)49.56 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 41.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MRKR Marker Therapeutics, Inc. PHARMA | 1.28 | -3.37 | $21.34M | 0.00% | -74.05% | -76.87% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2013 | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 183.06K | - | 205.99K | 0 | - | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | -675.13K | -313.29K | - | - | - | -1.03M | -1.14M | -1.74M | -1.75M | -2.43M | -2.72M | -2.42M | -2.39M | -3.99M | -3.20M | -4.67M | -4.43M | -5.64M | -5.87M | -5.65M | -6.64M | -6.36M | -7.38M | -8.78M | -10.91M | -10.02M | -9.79M | -5.27M | -5.83M | -4.31M | -4.13M | -3.20M | -2.55M | -2.31M | -2.40M | -4.96M | -4.26M | -2.14M | -4.07M |
| Net Income | -1.08M | -870.80K | - | -29.71M | 753.48K | -1.57M | -700.72K | -60.22M | 28.50M | -4.75M | 5.97M | -2.10M | -2.42M | -1.89M | -3.99M | -3.20M | -4.81M | -4.39M | -5.32M | -5.57M | -5.46M | -6.49M | -6.34M | -7.37M | -8.78M | -10.91M | -12.43M | -9.91M | -9.24M | -6.92M | -4.97M | 2.52M | -2.98M | -2.39M | -2.19M | -2.31M | -4.45M | -4.02M | -2.00M | -3.18M |
| Diluted EPS | - | - | - | - | - | -0.09 | - | -1.80 | 4.23 | - | 0.35 | -0.29 | - | -0.22 | -0.39 | - | - | - | - | - | - | - | - | - | -0.16 | -0.13 | -0.15 | -1.19 | -1.11 | -0.83 | -0.57 | 0.29 | -0.34 | -0.27 | -0.25 | -0.26 | -0.40 | -0.29 | -0.12 | -0.16 |
| R&D Expense | 242.98K | 54.40K | 30.00K | 22.50K | 22.50K | 32.50K | 609.38K | 201.16K | 968.76K | 985.75K | 1.25M | 1.11M | 989.09K | 1.20M | 1.62M | 1.60M | 1.83M | 1.88M | 2.83M | 3.15M | 3.12M | 3.82M | 4.28M | 4.80M | 5.64M | 7.35M | 6.78M | 7.03M | 2.92M | 3.59M | 3.38M | 2.38M | 2.04M | 2.58M | 2.34M | 3.47M | 3.14M | 4.18M | 2.35M | 2.84M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 183.06K | 205.99K | 213.19K | 500.00K | - | 0 | 3.31M | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 19.79M | 14.58M | 11.12M | 12.44M |
| Operating Income | - | - | - | - | - | - | - | - | - | - | -5.47M | -3.32M | - | -2.66M | -3.37M | -6.16M | -8.49M | -11.48M | -148.17M | -22.53M | -28.89M | - | -19.79M | -11.27M | -11.12M | -12.44M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.79M | -11.27M | -11.12M | -12.44M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.78M | -10.73M | -10.68M | -12.18M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 3.67K | 49.95K | -15.16K |
| Net Income | -935.33K | -671.99K | -2.28M | -5.78M | -2.68M | -985.60K | -1.30M | -3.89M | -2.20M | -17.35M | -3.53M | -2.03M | -5.86M | -5.53M | -30.88M | -34.07M | -2.46M | -10.98M | -147.96M | -21.43M | -28.71M | - | -29.93M | -8.24M | -10.73M | -12.16M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.30 | -0.72 | -1.16 | - | - | -0.61 | - | -3.58 | -0.94 | -1.19 | -0.79 |
| R&D Expense | - | - | - | - | - | - | - | - | - | - | 290.05K | 203.72K | 1.06M | 697.63K | 189.00K | 1.71M | 3.80M | 5.25M | 7.95M | 12.76M | 18.88M | 27.79M | 11.97M | 10.42M | 13.47M | 11.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 1999 | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | - | - | - | - | - | - | 116.43K | 307.92K | 104.21K | - | - | 6.65M | 7.92M | 5.18M | 62.14M | 46.36M | 45.61M | 68.14M | 34.42M | 17.13M | 22.02M | 19.07M |
| Total Equity | 100.37K | 252.23K | -74.05K | 465.83K | -643.75K | -2.44M | -2.22M | -3.00M | -1.67M | -3.02M | -1.78M | -3.87M | -3.46M | -6.04M | -8.77M | -1.02M | -21.36M | 6.18M | 3.66M | 59.34M | 44.09M | 27.34M | 43.99M | 19.60M | 14.05M | 18.56M | 16.80M |
| Cash & Equivalents | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.13M | 61.75M | 43.90M | 21.35M | 42.35M | 11.78M | 15.11M | 19.19M | 16.07M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.74M | 1.52M | 2.80M | 2.27M | 18.27M | 24.15M | 14.82M | 3.07M | 3.46M | 2.27M |
| Current Liabilities | - | - | - | - | - | - | - | - | - | - | - | 3.98M | 3.80M | 5.77M | 8.85M | 1.25M | 28.01M | 1.74M | 1.52M | 2.80M | 1.99M | 6.40M | 12.90M | 7.78M | 3.07M | 3.46M | 2.27M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -925.04K | -1.31M | - | -694.58K | -2.19M | -4.34M | -6.51M | -8.44M | -14.48M | -18.28M | -20.03M | -27.28M | -26.97M | -16.44M | -10.91M | -12.01M |
| Investing Cash Flow | - | - | - | - | - | - | - | 0 | -147.67K | -374.98K | -9.25M | -3.13M | -4.95M | 18.66M | - | - |
| Financing Cash Flow | 807.13K | 1.54M | 1.37M | 709.33K | 2.28M | 10.78M | 7.78M | 5.72M | 71.25M | 816.48K | 6.74M | 52.56M | 202.13K | 1.11M | 14.99M | 9.86M |
| Capital Expenditure | - | - | - | - | - | - | - | -0 | -147.67K | -374.98K | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | -8.44M | -14.63M | -18.66M | - | - | - | - | - | - |
| Share Buybacks | - | - | - | - | - | - | 0 | 310.49K | 71.71K | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2000 | Dec 2001 | Dec 2002 | Dec 2003 | Dec 2004 | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6,271.1% | -71,930.1% | -10,567.3% | -5,777.2% | - | - | -340.4% | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -5,999.1% | -71,826.3% | -10,050.9% | -5,741.2% | - | - | -248.8% | - | - |
| ROE % | -370.8% | 907.5% | -490.5% | 897.7% | 110.0% | 44.4% | 43.5% | 232.4% | 72.6% | 973.0% | 91.4% | 58.6% | 96.9% | 63.1% | 3,017.0% | 159.5% | -39.7% | -300.2% | -249.3% | -48.6% | -105.0% | - | -152.7% | -58.6% | -57.8% | -72.4% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | 141.5% | 94.9% | - | - | - | 28.8% | -137.3% | -313.8% | -249.7% | -50.8% | -73.7% | - | -74.3% | -80.2% | -59.9% | -74.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | NEA Management Company, LLC | 9.75% | 1.63M | $1.92M |
| 2 | Blue Owl Capital Holdings LP | 3.32% | 554.25K | $654.01K |
| 3 | Vanguard Capital Management LLC | 2.56% | 426.17K | $502.88K |
| 4 | Aisling Capital Management LP | 1.95% | 325.37K | $383.94K |
| 5 | Renaissance Technologies, LLC | 1.50% | 249.42K | $294.32K |
| 6 | Geode Capital Management, LLC | 0.84% | 139.82K | $164.98K |
| 7 | Osaic Holdings Inc. | 0.68% | 112.65K | $132.93K |
| 8 | Vanguard Fiduciary Trust Co | 0.52% | 87.27K | $102.98K |
| 9 | LPL Financial LLC | 0.50% | 83.15K | $98.11K |
| 10 | Concurrent Investment Advisors, LLC | 0.41% | 67.96K | $80.20K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MRKR
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOFkwNTJOenA0STZFTndDejV0VEZPQUtjR0FIVUxQOHhCc24zaEFROW03bzRUcVEyWWFiYnA5YWxpZUpEWlpuUG9BNE1hVGdkRUZGVFhxTXY3REMwcjNhVmxFck43SmtKUXdfdDAzZ19FcGFrU3RYRTdLejBPTkVFSFJwM1puSzU1Y196Qk…
MRKR Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1ldDhuRkFtVi01MG1DS3kyN2p1ajc4NDVzeFdnR0s4eHRPaFlCX1lLeUhpRXJmaUVXV1N5dnZJYzFkSWVUWnd0YUpBTDI4cGlYMUFvZEdqZ2pZdEVuNnlpWGpGRzZPMWxpUkpnb2M1anlRLVBtS3VHczZR?oc=5" target="_blank">MRK…
H.C. Wainwright reiterates Marker Therapeutics stock rating at buy - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPMWM2M0U2NzVrZ3M3MURudEN4em5UVGVFVHk3eGVrYUtvSHkxaVBHRDk2MWdfQWpLRjZWb0FSVnR1TVhwT2hpdElkdy01ZExwcTE4UmRaa0NnbXVkOWtCTTlhNy1Hc3dSSlJzTi1KTURlVWoxazRTVkRUTnAxMjNWeFhoNG50a0xDNng1cW…
MRKR - Marker Therapeutics Inc Stock Price and Quote - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9KcHFsbWUweDhQSFhHYmF6c1RXNmxWSS1GZGFFR21scmVEWV91S3hKOG9WWXQ2aE8tUXRLLXloUkhSTmlEVUE?oc=5" target="_blank">MRKR - Marker Therapeutics Inc Stock Price and Quote</a> <fon…
Marker Therapeutics, Inc.'s (NASDAQ:MRKR) Profit Outlook - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxPSG1YQUVYQmxWV0RmMXJpbW5YMEhvdUhvcHhJR2hNQXloZEZTVDVBVEM4R3hIYkZoRmM3RjdqalhhNXhRTHdjaTFhMUJTdXNxSTdIVldjTlA3SjYybm9YMElMb01rcm54amtaRGJpU2c3MDlHQVdvRF9rOGJaNzRhUU8zZmxrUGxNcUJrb3…
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1xTm1TWVJtY0d0YkFrXzFaU0RFNWJMNWNodkQ2T0FqQ1FDMUdPXzl2V3lEZGt4TmNDQk9sWVVKR0FPRG42X2JZTlJuUUZBTVRvYm5NU1d2aTNvTnVJNmNaUmlWT2xnTF95NHZFeDB5ZXZCaFBDUVBocg?oc=5" target="_blank">MRKR …
MRKR — Frequently Asked Questions
What is the current share price of Marker Therapeutics, Inc. (MRKR)?
As of 2026-09-19 21:16 PDT, Marker Therapeutics, Inc. (MRKR) trades at $1.28 on NasdaqCM. Its 52-week range is $0.85 to $2.19.
What is the market capitalisation of MRKR?
Marker Therapeutics, Inc. (MRKR) has a market capitalisation of $21.34M on NasdaqCM.
What is the P/E ratio of MRKR?
MRKR trades at a trailing price-to-earnings (P/E) ratio of -3.37. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.62.
What is the return on equity (ROE) of MRKR?
MRKR has a return on equity (ROE) of -76.87%. Its return on capital employed (ROCE) is -74.05%.
Is MRKR a good stock to buy?
This page provides a data-driven analysis of Marker Therapeutics, Inc. (MRKR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.